Akeso's Ivonescimab Meets Primary Endpoint in Phase 3 Biliary Tract Cancer Trial
MT Newswires Live
Yesterday
Akeso (HKG:9926) said its PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy met the primary endpoint in a Phase 3 trial for first-line treatment of advanced biliary tract cancer.
The trial met its primary endpoint of overall survival, with key secondary endpoints of progression-free survival and objective response rate also met, according to a Wednesday filing with the Hong Kong bourse.
The HARMONi-GI1 study enrolled 682 patients, marking ivonescimab's first positive Phase 3 result in gastrointestinal tumors, Akeso said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.